Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Italy / NCT05428371
Starting soon Observational

Assessment the Cancer Risk of Indeterminate Thyroid Nodules Through Integration of Clinical, Ultrasonographic and Multiomic Features

NCT05428371 · tracked via the Priya Life Science Italy tracker
Sponsor
University of Cagliari
Phase
Observational
Started
2023-01-01
Last updated
2022-06-23

Condition(s) studied

Thyroid NoduleThyroid Cancer

Investigational drug(s) / intervention(s)

Multiomic analyses of blood and surgical specimens

Multiomic analyses of blood and surgical specimens: The following items will be evaluated: * cell free dna length and integrity * presence or absence of SNPs in cfDNA and in DNA extracted from surgical samples * qualitative and quantitative evaluation of serum and surgical specimens proteome (proteomics)

Study summary

Indeterminate thyroid nodules have a mild risk of malignancy (15-30%). The aim of our study is to individuate new biomarkers of thyroid carcinoma through multiomic analyses of blood samples and of specimen samples of patients with indeterminate thyroid nodules.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients with indeterminate thyroid nodules (Class III and Class IV according to Bethesda Classification of thyroid nodules) Exclusion Criteria: * Patients with concomitant thyroid nodules of Bethesda Class V or Class VI * Patients with preoperative diagnosis of lymph node metastases of central or lateral neck compartment * Patients with distant metastases

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
AOU Cagliari Cagliari CA

More University of Cagliari trials in Italy

Biomarkers for Diagnosis and Treatment Response in Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS) Recruiting
FATAL-NSTI Study (Factors Associated With In-hospital mortALity in NSTI). Recruiting
Efficacy of tDCS in Degenerative Ataxia Active, not recruiting
PREdictive Risk Factors of Conversion Into Idiopathic RBD. Italian Study Recruiting
Prognotic Role of CMR in Takotsubo Syndrome Recruiting

Other trials for the same condition

Impact of Conventional Treatments and Clinical Variables on Thyroid Cancer Recruiting
Observational Study Analysing the Transcriptome and Mutational Status of Thyroid Carcinomas of Follicular Origin with Different Degrees of Malignancy Recruiting
The Unmet Needs of Cancer Survivors in Ausl IRCCS Reggio Emilia Recruiting
Myo-inositol and Selenium in Indeterminate Thyroid Nodules (TIR3a) Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05428371 on ClinicalTrials.gov ↗ ← All trials in Italy